ValamAi Highlights Founding Science Behind VMB-100, Published in Molecular Therapy – Nucleic Acids (2023)

ValamAi highlighted “Local application of engineered insulin-like growth factor I mRNA demonstrates regenerative therapeutic potential in vivo,” the peer-reviewed publication underpinning VMB-100 (Antony JS et al., Molecular Therapy – Nucleic Acids, 2023), ValamAi’s lead engineered IGF-I mRNA candidate. The preclinical data demonstrate accelerated functional recovery and tissue regeneration, supporting the ongoing clinical development of the program in stress urinary incontinence.

The publication includes in vivo data from a disc herniation model, in which treatment reduced the loss of disc height index versus vehicle over 90 days post-injury. In a rat model of stress urinary incontinence, a single intra-urethral injection of VMB-100 demonstrated substantial regeneration of the urinary sphincter muscle. The publication forms part of the scientific foundation supporting the company’s FDA IND clearance for VMB-100.

ValamAi continues to build on this founding science as it advances VMB-100 toward a Phase IIa study in women with stress urinary incontinence, and explores indication expansion into disc herniation.